<style> .wpb_animate_when_almost_visible { opacity: 1; }</style>

News

HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 21, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held on June 21, 2019 in Toronto, Ontario.

A total of 23,983,572 Common Shares, or 86.86% of the total Common Shares issued and outstanding, were voted by proxy at the meeting. Each director nominee was elected by a show of hands. Based on proxies received prior to the meeting, voting by individual director was as follows:

Nominees

Votes For

% For

Votes Withheld

% Withheld

William Wells

23,717,151

100.00

558

0.00

Greg Gubitz

23,717,187

100.00

522

0.00

J. Spencer Lanthier

23,686,373

99.87

31,336

0.13

Yvon Bastien

23,689,313

99.88

28,396

0.12

Rodney Hill

23,686,610

99.87

31,099

0.13

Don DeGolyer

23,689,546

99.88

28,163

0.12

Laura Brege

23,673,939

99.82

43,770

0.18

 

Shareholders also voted in favour of the re-appointment of Ernst & Young LLP as HLS's auditors.  

ABOUT HLS THERAPEUTICS INC.              
Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

For further information: Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, dave.mason@loderockadvisors.com; Gilbert Godin, President and Chief Operating Officer, HLS Therapeutics Inc., (484) 232-3400 ext101, g.godin@hlstherapeutics.com